Evidence map›Paper›PMID 30082843›Full record

ArticleScientific reports2018

Antibiotic resistance, molecular characterizations, and clinical manifestations of Campylobacteriosis at a military medical center in Hawaii from 2012-2016: a retrospective analysis.

Evan C Ewers, Sarah K Anisowicz, Tomas M Ferguson, Scott E Seronello, Jason C Barnhill, Michael B Lustik, Willie Agee, Michael A Washington, Md A Nahid, Mark W Burnett and 10 more

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Insights on the genomic diversity, virulence and resistance profile of a Campylobacter jejuni strain isolated from a hospitalized patient in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Evan C EwersTripler Army Medical Center, Honolulu, HI, USA. evan.c.ewers.mil@mail.mil.ORCID 0000-0002-1384-9973
Sarah K AnisowiczTripler Army Medical Center, Honolulu, HI, USA.
Tomas M FergusonTripler Army Medical Center, Honolulu, HI, USA.
Scott E SeronelloTripler Army Medical Center, Honolulu, HI, USA.
Jason C BarnhillTripler Army Medical Center, Honolulu, HI, USA.
Michael B LustikTripler Army Medical Center, Honolulu, HI, USA.
Willie AgeeTripler Army Medical Center, Honolulu, HI, USA.
Michael A WashingtonTripler Army Medical Center, Honolulu, HI, USA.
Md A NahidTripler Army Medical Center, Honolulu, HI, USA.
Mark W BurnettTripler Army Medical Center, Honolulu, HI, USA.
Ladaporn BodhidattaArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Apichai SrijanArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Supaporn RukasiriArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Patcharawalai WassanarungrojArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Sirigade RuekitArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Panida NobthaiArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Brett E SwierczewskiArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Woradee LurchachaiwongArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Oralak SerichantalergsArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Viseth NgauyTripler Army Medical Center, Honolulu, HI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hawaii has one of the highest incidences of Campylobacteriosis in the United States, but there remains little published data on circulating strains or antimicrobial resistance. We characterized 110 clinical Campylobacter isolates (106 C. jejuni, 4 C. coli) processed at Tripler Army Medical Center in Honolulu, HI from 2012-2016. Twenty-five percent of C. jejuni isolates exhibited fluoroquinolone (FQ) resistance, compared with 16% for tetracycline (TET), and 0% for macrolides. Two of the four C. coli isolates were resistant to FQ, TET, and macrolides. C. jejuni isolates further underwent multilocus sequence typing, pulsed-field gel electrophoresis, and molecular capsular typing. Nineteen capsule types were observed, with two capsule types (HS2 and HS9) being associated with FQ resistance (p < 0.001 and p = 0.006, respectively). HS2 FQ-resistant isolates associated with clonal complex 21, possibly indicating clonal spread in FQ resistance. Macrolides should be considered for treatment of suspect cases due to lack of observed resistance.

Indexed as

AdultAnti-Bacterial AgentsCampylobacterCampylobacter InfectionsDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldFemaleFluoroquinolonesHawaiiHumansMacrolidesMaleMultilocus Sequence TypingRetrospective StudiesTetracyclineYoung AdultAnti-Bacterial AgentsFluoroquinolonesMacrolidesTetracycline

Identifiers

PMID30082843
PMCPMC6078982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.